The Journal of Rheumatology · 2022 · 17 citations · 30 references
MedicineHematologyPediatricsEvidence-based PracticePediatric HematologyPediatric RheumatologyClinical HematologyEvidence-based MedicineClinical Guideline Evidence ReviewConsensus Building MechanismsExpert Opinion EvidenceHematologic Outcome AssessmentHospital Stay DurationMeeting Consensus BuildingPatient Outcomes MeasurementSystematic Literature Review
Objective To compare clinical outcomes in children with hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) who were managed before and after implementation of an evidence-based guideline (EBG). Methods A management algorithm for MAS-HLH was developed at our institution based on literature review, expert opinion, and consensus building across multiple pediatric subspecialties. An electronic medical record search retrospectively identified hospitalized patients with MAS-HLH in the pre-EBG (October 15, 2015, to December 4, 2017) and post-EBG (January 1, 2018, to January 21, 2020) time periods. Predetermined outcome metrics were evaluated in the 2 cohorts. Results After the EBG launch, 57 children were identified by house staff as potential patients with MAS-HLH, and rheumatology was consulted for management. Ultimately, 17 patients were diagnosed with MAS-HLH by the treating team. Of these, 59% met HLH 2004 criteria, and 94% met 2016 classification criteria for MAS complicating systemic juvenile idiopathic arthritis. There was a statistically significant reduction in mortality from 50% before implementation of the EBG to 6% in the post-EBG cohort ( P = 0.02). There was a significant improvement in time to 50% reduction in C-reactive protein level in the post-EBG vs pre-EBG cohorts (log-rank P < 0.01). There were trends toward faster time to MAS-HLH diagnosis, faster initiation of immunosuppressive therapy, shorter length of hospital stay, and more rapid normalization of MAS-HLH–related biomarkers in the patients post-EBG. Conclusion While the observed improvements may be partially attributed to advances in treatment of MAS-HLH that have accumulated over time, this analysis also suggests that a multidisciplinary treatment pathway for MAS-HLH contributed meaningfully to favorable patient outcomes.
30
HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis
Jan‐Inge Henter, AnnaCarin Horne, Maurizio Aricò et al. · Pediatric Blood & Cancer · 2006 · 5.3K citations
Medicine, Hematology, Immunology +17
Perforin Gene Defects in Familial Hemophagocytic Lymphohistiocytosis
Susan E. Stepp, Rémi Dufourcq-Lagelouse, Françoise Le Deist et al. · Science · 1999 · 1.2K citations
Life Sciences, Genetics, Immunology +15
Bita Shakoory, Joseph A. Carcillo, W. Winn Chatham et al. · Critical Care Medicine · 2015 · 854 citations · Full text